Skip to content
Clinical Trials – home

Azienda Ospedaliero Universitaria Di Modena

Verified siteinfo

Italy Largo Del Pozzo 71, 41124 Modena, Italy

  • 147 trials recruiting
  • Idiopathic pulmonary fibrosis · Non-small cell lung cancer · Breast cancer
  • Adults and children

About Specializations

Azienda Ospedaliero Universitaria Di Modena in Modena, Italy specialises in clinical trials of conditions such as Idiopathic pulmonary fibrosis, Non-small cell lung cancer, Breast cancer, Hormone receptor positive HER2 negative breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory and Infectious Diseases

At Azienda Ospedaliero Universitaria Di Modena, research in Respiratory Tract Diseases and Virus Diseases focuses on conditions such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, bronchiectasis, and post-acute COVID syndrome. These studies are designed to better understand disease progression and evaluate new treatment strategies for people with complex lung and infectious diseases.

  • Chronic lung disease, including COPD, bronchiectasis, and progressive pulmonary fibrosis
  • Severe respiratory conditions such as idiopathic pulmonary fibrosis and acute respiratory distress syndrome
  • Infectious disease research covering HIV, hepatitis B, fungal infections, and recurrent Clostridioides difficile infection
  • Trials aiming to improve symptom control, reduce complications, and assess treatment effectiveness

The site also contributes to studies in immune system diseases linked to respiratory inflammation and infection-related complications.

Oncology Across Solid Tumors

A major part of the trial portfolio at this hospital in Modena is devoted to Neoplasms, with a strong emphasis on breast cancer, lung cancer, gastrointestinal cancers, ovarian cancer, and pancreatic cancer. The research is centered on testing new therapies, improving outcomes after standard treatment, and finding better ways to delay recurrence or spread.

  • Breast cancer, including HER2-positive, HER2-negative, triple-negative, and hormone receptor-positive disease
  • Lung cancer studies spanning non-small cell and small cell disease
  • Gastric, colorectal, pancreatic, and head and neck cancers
  • Studies evaluating new combinations, maintenance approaches, and post-surgery treatment strategies

Many of these trials explore whether emerging cancer therapies can improve survival or extend the time before disease progression.

Hematology, Blood Disorders, and Cellular Therapy

The research program includes extensive work in Hemic and Lymphatic Diseases, especially acute leukemias, chronic lymphocytic leukemia, lymphomas, multiple myeloma, and inherited or acquired blood disorders. These studies are aimed at refining treatment choices, supporting deeper disease control, and improving long-term outcomes for patients with difficult-to-treat hematologic conditions.

  • Acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia
  • Chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma
  • Multiple myeloma and other plasma cell disorders
  • Blood-related conditions such as sickle cell disease, thalassemia, and thrombocytopenia

This area includes trials testing new drug combinations and strategies to reduce relapse risk and improve disease response.

Autoimmune, Inflammatory, and Kidney Diseases

Research in Immune System Diseases, Skin and Connective Tissue Diseases, and kidney disorders addresses illnesses such as systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, IgA nephropathy, and lupus nephritis. The goal is to evaluate treatments that can better control inflammation, protect organ function, and reduce long-term complications.

  • Autoimmune diseases affecting the kidneys, joints, skin, and internal organs
  • Inflammatory bowel disease, including ulcerative colitis
  • Renal conditions such as IgA nephropathy, chronic kidney disease, and end-stage kidney disease
  • Trials focused on symptom relief, disease control, and preservation of kidney function

The site also studies hidradenitis suppurativa, psoriasis, and other chronic inflammatory skin conditions.

Neurology and Neurodegenerative Research

A notable part of the portfolio covers Nervous System Diseases and neurodegenerative disorders, including multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, and epilepsy. These trials are intended to test new therapies, improve symptom management, and slow disease progression in conditions that can strongly affect daily life.

  • Multiple sclerosis and relapsing inflammatory neurological disease
  • Alzheimer’s disease, frontotemporal dementia, and related cognitive disorders
  • Amyotrophic lateral sclerosis and other progressive neurodegenerative illnesses
  • Headache, migraine, and refractory epilepsy research

Research in this area often aims to preserve function, reduce relapses, and improve quality of life over time.

Cardiovascular, Metabolic, and Liver Health

The site also conducts studies in Cardiovascular Diseases, Nutritional and Metabolic Diseases, and Digestive System Diseases. Key topics include atherosclerotic cardiovascular disease, hypertension, atrial fibrillation, metabolic dysfunction-associated steatohepatitis, and primary biliary cholangitis. These trials are focused on prevention, risk reduction, and better long-term disease management.

  • Heart and vascular disease, including elevated cardiovascular risk and atrial fibrillation
  • Liver and biliary disorders such as MASH/NASH, primary biliary cholangitis, and chronic hepatitis B
  • Metabolic conditions including severe hypertriglyceridemia and obesity-related disease
  • Studies evaluating whether new treatments can reduce complications and improve clinical outcomes

This research reflects a broad interest in preventing major organ damage and improving chronic disease control.

Pediatric, Rare, and Specialized Conditions

Beyond the major disease groups, Azienda Ospedaliero Universitaria Di Modena participates in trials for rare diseases, congenital disorders, and selected pediatric conditions. Examples include Langerhans cell histiocytosis, Prader-Willi syndrome, generalized epidermolysis bullosa simplex, and congenital adrenal hyperplasia. These studies aim to improve diagnosis, refine treatment options, and address unmet needs in less common diseases.

  • Rare inherited and developmental disorders
  • Pediatric hematology and oncology, including leukemia and neuroblastoma
  • Specialized reproductive and pregnancy-related research
  • Trials designed to generate better care options where standard treatments are limited

The breadth of this work shows a strong commitment to both common and uncommon conditions across the clinical spectrum.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Largo Del Pozzo 7141124 ModenaItaly
Recruiting now
147 trials
Conditions studied
221
Partner status
Verified site

More sites in ModenaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

359 clinical trials

Safety Study of NB-4746 with Riluzole and Placebo in Adults with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Riluzole

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

A study to evaluate the effectiveness and safety of pridopidine hydrochloride in patients with amyotrophic lateral sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Ferrer Internacional S.A.

A study to evaluate the effectiveness and safety of usnoflast in adults with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Usnoflast
  • Sponsor:Zydus Therapeutics Inc.

Asthma

Recruiting

Study to evaluate the long-term safety and effectiveness of lunsekimig in adults with moderate to severe asthma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.